BETA
Musculoskeletal technology manufacturer spanning spine implants, surgical robotics and imaging, orthopedic trauma, joint reconstruction and Nevro spinal cord stimulation.
Globus Medical, Inc. is a publicly traded medical device manufacturer headquartered in Audubon, Pennsylvania. Founded in 2003, it supplies implants, instruments and enabling technologies across spine, orthopedic trauma and joint reconstruction, alongside acquired neuromodulation and supporting services.
The company reported approximately US$2.94 billion in worldwide net sales for 2025 and more than 6,000 employees at year-end. The NuVasive merger completed in September 2023 expanded its spine and enabling technology portfolio; the April 2025 Nevro acquisition added spinal cord stimulation for chronic pain.
Its current portfolio combines implants with planning, navigation, robotics, imaging and connected care. In August 2026, Globus announced the acquisition of Higgs Boson Health. Its October 2026 SCRIPT patient-specific implant announcement described a preview ahead of commercialization; that preview is kept separate from the marketed product selection.
Covers Globus Medical and selected NuVasive- and Nevro-origin businesses as of October 28, 2026. The snapshots emphasize manufacturer U.S. documentation. Historical related-model safety records are distinguished from current product selection.
Fixation, interbody fusion, cervical motion preservation and lateral-access workflows, including NuVasive-origin technologies. Selected examples distinguish CREO, expandable RISE, porous HEDRON T and Simplify; XLIF is a procedural platform. [51][55][53][56][5]
ExcelsiusGPS supports spine and cranial navigation; Excelsius3D provides imaging; ExcelsiusFlex supports knee arthroplasty. Related technologies include ExcelsiusHub and XR. [47][45][46]
Fracture fixation and magnetically adjustable limb reconstruction. ANTHEM ankle fixation and the Precice IMLL family are selected examples; historical Precice device variants require separate safety interpretation. [50][54][37]
Hip and knee implants and associated workflows. ACTIFY 3D illustrates knee reconstruction; the manufacturer also lists unicondylar knee and hip reconstruction options. [44][49]
The acquired Nevro business adds spinal cord stimulation and connected therapy management. HFX iQ and AdaptivAI are grouped as a hardware-and-therapy platform. [57]
Powered instruments, regenerative biologics, intraoperative neuromonitoring services and registry tools broaden the portfolio. The Higgs Boson Health acquisition adds digital patient/provider experience capabilities; these services are not all device products. [52][43][38][1]
The portfolio also spans biologics, clinical services, digital health and additional implant configurations.
Selected FDA evidence includes nine 510(k) decisions associated with the displayed families. Matching uses native applicant and device identity: unrelated CREO, ANTHEM and HFX names are excluded. ANTHEM ankle-specific authorization mapping remains unresolved. [11][13][17][10][9][12][14][16][15]
Simplify has an original PMA, P200022, and a later panel-track supplement for one- or two-level use. Nevro HFX iQ is documented through P130022/S044. Supplements are not counted as new original PMAs, and this does not establish authorization for every connected software feature. [7][8][6]
Selected recall records concern ExcelsiusGPS accessories, specified Simplify devices, and distinct Precice labeling or models. Precice Max and STRYDE appear only as related-model safety context. FDA’s June 2023 communication updates earlier IMLL labeling; a historical recall record should not be read as a blanket restriction on every current Precice implant. [22][23][24][21][20][25][18][19][37]
Counts are documented minimums. Alias, accessory and subsidiary coverage remains incomplete. [48]
Latest recorded source review: 2026-10-28.
Scope: selected product families.
| Recalled product / record | Initiated | Source |
|---|---|---|
| September 30, 2024 | [25][35] |
| December 15, 2023 | [24][34] |
| December 11, 2023 | [23][31][32][33] |
| December 7, 2023 | [22][30] |
| June 20, 2022 | [21][29] |
| October 29, 2021 | [20][28] |
| February 12, 2021 | [18][26] |
| February 12, 2021 | [19][27] |
Selected product families from the company’s commercial portfolio.
Robotic guidance and navigation platform for spine and cranial procedures. The robotic arm and navigation software are grouped together; authorized modules, compatible instruments and imaging workflows must be checked separately. [47][11]
FDA-clearedListed on the manufacturer’s product site; configuration, current supply and local availability require confirmation.
Mobile imaging platform combining digital radiography, fluoroscopy and 3D imaging. It can support an integrated workflow with ExcelsiusGPS; the imaging system remains a distinct equipment purchase. [45][13]
FDA-clearedListed on the manufacturer’s product site; configuration, current supply and local availability require confirmation.
Robotic navigation platform for total knee arthroplasty with CT-based and imageless workflows. The platform includes its workflow components and attachments. [46][17]
FDA-clearedListed on the manufacturer’s product site; configuration, current supply and local availability require confirmation.
Spinal fixation system using screws, rods and associated instruments with a 5.5 mm rod architecture. This profile covers CREO 5.5. [51][10]
FDA-clearedListed on the manufacturer’s product site; configuration, current supply and local availability require confirmation.
Titanium expandable lumbar interbody spacer for posterior approaches such as TLIF and PLIF. Supplemental fixation is required. Sizes are grouped; other expandable platforms are outside this selected example. [55][9]
FDA-clearedListed on the manufacturer’s product site; configuration, current supply and local availability require confirmation.
Porous, 3D printed interbody spacer for transforaminal lumbar fusion, with an articulating insertion workflow. This profile covers HEDRON T. [53][12]
FDA-clearedListed on the manufacturer’s product site; configuration, current supply and local availability require confirmation.
Artificial cervical disc for motion-preserving reconstruction in eligible patients. FDA evidence distinguishes the original one-level approval from the later supplement covering one or two contiguous levels. [56][7][8]
FDA PMA approvedListed on the manufacturer’s product site; configuration, current supply and local availability require confirmation.
Magnetically adjustable intramedullary limb-lengthening system operated with an external controller. The selected scope is the IMLL family; Precice Max, STRYDE, Bone Transport and Plate require separate model-specific safety and availability checks. [54][14][37]
FDA-clearedListed on the manufacturer’s product site; configuration, current supply and local availability require confirmation.
Anatomically contoured plate, screw and instrument system for ankle fracture fixation. This selected example covers ankle anatomy; the wider ANTHEM fracture portfolio is not cataloged model by model. [50]
Marketed · regulatory scope variesListed on the manufacturer’s product site; configuration, current supply and local availability require confirmation.
Cementless total knee replacement system with porous implant interfaces and compatible instrumentation. [49][16]
FDA-clearedListed on the manufacturer’s product site; configuration, current supply and local availability require confirmation.
Oscillating instrument platform for bone removal, tissue cutting and pilot-hole drilling. Handpieces and attachments stay within one system; navigated configurations require their own compatibility and labeling checks. [52][15]
FDA-clearedListed on the manufacturer’s product site; configuration, current supply and local availability require confirmation.
Nevro spinal cord stimulation platform with an implantable pulse generator, patient app and therapy-management technology for specified chronic pain indications. The hardware and connected therapy features are grouped; eligibility depends on current labeling. [57][6]
FDA PMA approvedListed on the manufacturer’s product site; configuration, current supply and local availability require confirmation.
Announced a SCRIPT patient-specific implant preview ahead of commercialization and new XLIF Prone positioning/access technologies at NASS 2026. [5]
Company announced CE marking for commercial sale in the EU and UK. This milestone is a manufacturer announcement, not an independently audited certificate. [2]
Added digital patient/provider experience capabilities to the broader Globus ecosystem. [1]
Added spinal cord stimulation and chronic pain therapy technologies. [58]
NuVasive became a wholly owned subsidiary, expanding spine implants, procedural technologies and related capabilities. [58]
Accessed 10/29/2026